FamiCord Group Nakiller
Filter by:
| No. | Cell source | Indication | Area of medicine | Year | Type of therapy | Country | Age |
|---|---|---|---|---|---|---|---|
| 1 | cord blood | talassemia major | hematology | 2018 | standard therapy | Turkey | 9,5 |
| 2 | autologous cord blood | aplastic anaemia | hematology | 2018 | standard therapy | Poland | 3,5 |
| 3 | cord blood | chronic granulomatous disease | hematology | 2017 | standard therapy | Turkey | 3,9 |
| 4 | autologous cord blood | autism | neurology | 2017 | experimental therapy | Poland | 4,1 |
| 5 | autologous cord blood | autism | neurology | 2017 | experimental therapy | Poland | 4,1 |
| 6 | autologous cord blood | autism | neurology | 2017 | experimental therapy | Poland | 5,4 |
| 7 | autologous cord blood | autism | neurology | 2017 | experimental therapy | Poland | 7,3 |
| 8 | autologous cord blood | autism | neurology | 2017 | experimental therapy | Poland | 6,2 |
| 9 | autologous cord blood | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 6,8 |
| 10 | cord blood | relapse of acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 7,3 |
| 11 | autologous cord blood | autism | neurology | 2017 | experimental therapy | Poland | 4,11 |
| 12 | autologous cord blood | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 10,3 |
| 13 | autologous cord blood | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 5,4 |
| 14 | autologous cord blood | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 2,2 |
| 15 | cord blood | talassemia major | hematology | 2017 | standard therapy | Turkey | 4,1 |
| 16 | cord blood | talassemia major | hematology | 2017 | standard therapy | Turkey | 4,0 |
| 17 | cord blood | CD40 ligand deficiency | hematology | 2017 | standard therapy | Turkey | 9,6 |
| 18 | cord blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Hungary | 7 |
| 19 | autologous cord blood | autism | neurology | 2016 | experimental therapy | Poland | 6 |
| 20 | cord blood + peripheral blood | acute myeloid leukemia | hematology | 2016 | standard therapy | Jordan | 6 |
| 21 | cord blood | acute lymphoblastic leukemia | hematology | 2015 | standard therapy | Poland | 4 |
| 22 | cord blood | acute lymphoblastic leukemia | hematology | 2014 | standard therapy | Turkey | 7 |
| 23 | cord blood | X - linked lymphoproliferative syndrome | hematology | 2013 | standard therapy | Poland | 10/12 |
| 24 | cord blood | beta-talassemia, agranulocytosis | hematology | 2013 | standard therapy | Turkey | 8 |
| 25 | cord blood | acute myeloid leukemia | hematology | 2013 | standard therapy | Poland | 3 |
| 26 | cord blood | aplastic anaemia | hematology | 2013 | standard therapy | Poland | 3 |
| 27 | cord blood | T-acute lymphoblastic leukemia | hematology | 2012 | standard therapy | Turkey | 5 |
| 28 | cord blood | talassemia major, acute lymphoblastic leukemia | hematology | 2012 | standard therapy | Turkey | 3,5 |
| 29 | cord blood | anaemia, talassemia major | hematology | 2012 | standard therapy | Turkey | 6 |
| 30 | cord blood | severe aplastic anaemia | hematology | 2012 | standard therapy | Hungary | 3 |
| 31 | cord blood | chronic granulomatous disease | hematology | 2011 | standard therapy | Poland | 7,5 |
| 32 | cord blood | histiocytosis | hematology | 2011 | standard therapy | Poland | 2,5 |
| 33 | cord blood | acute lymphoblastic leukemia | hematology | 2011 | standard therapy | Poland | 5 |
| 34 | cord blood | acute myeloid leukemia | hematology | 2011 | standard therapy | Hungary | 2 |
| 35 | cord blood | Fanconi anemia | hematology | 2011 | standard therapy | Poland | 12 |
| 36 | cord blood | pre -B acute lymphoblastic leukemia | hematology | 2010 | standard therapy | Hungary | 1,5 |
| 37 | cord blood | myelodysplastic syndrome | hematology | 2009 | standard therapy | Poland | 5 |
| 38 | autologous cord blood | cerebral ischemia | neurology | 2008 | experimental therapy | Poland | 1,5 |
| 39 | cord blood | acute lymphoblastic leukemia | hematology | 2008 | standard therapy | Poland | 5 |
| 40 | cord blood | neuroblastoma | hematology | 2007 | standard therapy | Poland | 8 |
| 41 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 68,5 |
| 42 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 31,11 |
| 43 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 25,5 |
| 44 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 36,3 |
| 45 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 61,11 |
| 46 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2018 | experimental therapy | Poland | 16,7 |
| 47 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2018 | experimental therapy | Poland | 44,11 |
| 48 | cord tissue (Wharton's jelly) | cerebral palsy, epilepsy | neurology | 2018 | experimental therapy | Poland | 3,7 |
| 49 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2018 | experimental therapy | Poland | 59,10 |
| 50 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 48,11 |
| 51 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 44,3 |
| 52 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 52,8 |
| 53 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2018 | experimental therapy | Poland | 2,6 |
| 54 | cord tissue (Wharton's jelly) | myopathy | neurology | 2018 | experimental therapy | Poland | 57,3 |
| 55 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2018 | experimental therapy | Poland | 28,1 |
| 56 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2018 | experimental therapy | Poland | 66,8 |
| 57 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 67,10 |
| 58 | cord tissue (Wharton's jelly) | other specific disorders of the central nervous system | neurology | 2018 | experimental therapy | Poland | 1,11 |
| 59 | cord tissue (Wharton's jelly) | degeneration of the cartilage of the knee joint | orthopedics | 2018 | experimental therapy | Poland | 34,7 |
| 60 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 41,8 |
| 61 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 32,3 |
| 62 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 46,7 |
| 63 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2018 | experimental therapy | Poland | 39,5 |
| 64 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 55,4 |
| 65 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 36,6 |
| 66 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 34,11 |
| 67 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 27,2 |
| 68 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2018 | experimental therapy | Poland | 3,1 |
| 69 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2018 | experimental therapy | Poland | 33,11 |
| 70 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 52,3 |
| 71 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 66,3 |
| 72 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 47,8 |
| 73 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 59,3 |
| 74 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 50,8 |
| 75 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 51,9 |
| 76 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 38,6 |
| 77 | cord tissue (Wharton's jelly) | developmental delay | neurology | 2018 | experimental therapy | Poland | 14 |
| 78 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 46,2 |
| 79 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 38,1 |
| 80 | cord tissue (Wharton's jelly) | spinal cord injury | neurology | 2018 | experimental therapy | Poland | 30,9 |
| 81 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 65,2 |
| 82 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2018 | experimental therapy | Poland | 20,9 |
| 83 | cord tissue (Wharton's jelly) | age-related macular degeneration | ophthalmology | 2018 | experimental therapy | Poland | 46,7 |
| 84 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 30,4 |
| 85 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2018 | experimental therapy | Poland | 44,2 |
| 86 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 34,2 |
| 87 | cord tissue (Wharton's jelly) | age-related macular degeneration | ophthalmology | 2018 | experimental therapy | Poland | 20,6 |
| 88 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 55,8 |
| 89 | cord tissue (Wharton's jelly) | cerebral palsy, epilepsy | neurology | 2018 | experimental therapy | Poland | 9,2 |
| 90 | cord tissue (Wharton's jelly) | stroke | neurology | 2018 | experimental therapy | Poland | 70,1 |
| 91 | cord tissue (Wharton's jelly) | Friedreich's ataxia | neurology | 2018 | experimental therapy | Poland | 27,6 |
| 92 | cord tissue (Wharton's jelly) | Friedreich's ataxia | neurology | 2018 | experimental therapy | Poland | 31,5 |
| 93 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2018 | experimental therapy | Poland | 46,1 |
| 94 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 47,3 |
| 95 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 52,11 |
| 96 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 28,6 |
| 97 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2018 | experimental therapy | Poland | 3,8 |
| 98 | cord tissue (Wharton's jelly) | autism | neurology | 2018 | experimental therapy | Poland | 8,5 |
| 99 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 62,5 |
| 100 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2018 | experimental therapy | Poland | 21,7 |
| 101 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 40,0 |
| 102 | cord tissue (Wharton's jelly) | developmental delay | neurology | 2018 | experimental therapy | Poland | 7,11 |
| 103 | cord tissue (Wharton's jelly) | autism | neurology | 2018 | experimental therapy | Poland | 9,0 |
| 104 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2018 | experimental therapy | Poland | 2,11 |
| 105 | cord tissue (Wharton's jelly) | autism | neurology | 2018 | experimental therapy | Poland | 8,3 |
| 106 | cord tissue (Wharton's jelly) | autism | neurology | 2018 | experimental therapy | Poland | 6,10 |
| 107 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2018 | experimental therapy | Poland | 54,8 |
| 108 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 54,2 |
| 109 | cord tissue (Wharton's jelly) | damage to the intercondylar fissure of the right knee | orthopedics | 2018 | experimental therapy | Poland | 40,2 |
| 110 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2018 | experimental therapy | Poland | 7,0 |
| 111 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 67,11 |
| 112 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 41,9 |
| 113 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 35 |
| 114 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 83,5 |
| 115 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 57,8 |
| 116 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 57,5 |
| 117 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 45,11 |
| 118 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 28,6 |
| 119 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 61,3 |
| 120 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 20,8 |
| 121 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2018 | experimental therapy | Poland | 34,1 |
| 122 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 75,5 |
| 123 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2018 | experimental therapy | Poland | 4,11 |
| 124 | cord tissue (Wharton's jelly) | dystrophia myotonica | neurology | 2018 | experimental therapy | Poland | 27,4 |
| 125 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 80,3 |
| 126 | cord tissue (Wharton's jelly) | cerebral palsy, epilepsy | neurology | 2018 | experimental therapy | Poland | 2,4 |
| 127 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2018 | experimental therapy | Poland | 9,4 |
| 128 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 76,1 |
| 129 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 54,4 |
| 130 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 35,1 |
| 131 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 80,5 |
| 132 | cord tissue (Wharton's jelly) | spinal cord injury | neurology | 2018 | experimental therapy | Poland | 25,9 |
| 133 | cord tissue (Wharton's jelly) | holoprosencephalia | neurology | 2018 | experimental therapy | Poland | 12,2 |
| 134 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2018 | experimental therapy | Poland | 8,8 |
| 135 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2018 | experimental therapy | Poland | 22,6 |
| 136 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 65,7 |
| 137 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 65,2 |
| 138 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 60,2 |
| 139 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 31,2 |
| 140 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 40,9 |
| 141 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 70,11 |
| 142 | cord tissue (Wharton's jelly) | autism | neurology | 2018 | experimental therapy | Poland | 9,5 |
| 143 | cord tissue (Wharton's jelly) | other specific disorders of the central nervous system | neurology | 2018 | experimental therapy | Poland | 1,9 |
| 144 | cord tissue (Wharton's jelly) | cerebral palsy, epilepsy | neurology | 2018 | experimental therapy | Poland | 10,9 |
| 145 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 64,4 |
| 146 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 47,1 |
| 147 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 66,2 |
| 148 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2018 | experimental therapy | Poland | b/d |
| 149 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 75,7 |
| 150 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2018 | experimental therapy | Poland | 4,11 |
| 151 | cord tissue (Wharton's jelly) | encephalopathy, cerebral palsy | neurology | 2018 | experimental therapy | Poland | 22,1 |
| 152 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2018 | experimental therapy | Poland | 13,1 |
| 153 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2018 | experimental therapy | Poland | 2,4 |
| 154 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2018 | experimental therapy | Poland | 6,2 |
| 155 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 67,9 |
| 156 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 62 |
| 157 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 38,2 |
| 158 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2018 | experimental therapy | Poland | 44,0 |
| 159 | cord tissue (Wharton's jelly) | stroke | neurology | 2018 | experimental therapy | Poland | 53,4 |
| 160 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2018 | experimental therapy | Poland | 3,10 |
| 161 | cord tissue (Wharton's jelly) | Other reduction deformities of brain, Schizencephaly | neurology | 2018 | experimental therapy | Poland | 5,7 |
| 162 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 49,2 |
| 163 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2018 | experimental therapy | Poland | 4,5 |
| 164 | cord tissue (Wharton's jelly) | arthrogryposis multiplex congenita, epilepsia | neurology | 2018 | experimental therapy | Poland | 6,3 |
| 165 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 64,5 |
| 166 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 63,7 |
| 167 | cord tissue (Wharton's jelly) | autism | neurology | 2018 | experimental therapy | Poland | 5,11 |
| 168 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2018 | experimental therapy | Poland | 39,1 |
| 169 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2018 | experimental therapy | Poland | 47,3 |
| 170 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 67,1 |
| 171 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2018 | experimental therapy | Poland | 64,7 |
| 172 | cord tissue (Wharton's jelly) | spinal cord injury | neurology | 2018 | experimental therapy | Poland | 25,9 |
| 173 | cord tissue (Wharton's jelly) | autism | neurology | 2018 | experimental therapy | Poland | 6,3 |
| 174 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2018 | experimental therapy | Poland | 13,3 |
| 175 | cord tissue (Wharton's jelly) | autism | neurology | 2018 | experimental therapy | Poland | 7,1 |
| 176 | cord tissue (Wharton's jelly) | autism | neurology | 2018 | experimental therapy | Poland | 11,11 |
| 177 | cord tissue (Wharton's jelly) | delayed psychomotor development, atrophy of the optic nerves | neurology | 2018 | experimental therapy | Poland | 2,0 |
| 178 | cord tissue (Wharton's jelly) | other specific disorders of the central nervous system | neurology | 2018 | experimental therapy | Poland | 16,1 |
| 179 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2018 | experimental therapy | Poland | 5,11 |
| 180 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2018 | experimental therapy | Poland | 28,11 |
| 181 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2018 | experimental therapy | Poland | 62,1 |
| 182 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 67,11 |
| 183 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 37,9 |
| 184 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 71,7 |
| 185 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | no data |
| 186 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 7,11 |
| 187 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 47,6 |
| 188 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2017 | experimental therapy | Poland | 44,1 |
| 189 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 34,11 |
| 190 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 58,10 |
| 191 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 49,0 |
| 192 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 37,4 |
| 193 | cord tissue (Wharton's jelly) | dystrophia myotonica | neurology | 2017 | experimental therapy | Poland | 37,7 |
| 194 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 26,11 |
| 195 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 56,7 |
| 196 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 48,11 |
| 197 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 46,3 |
| 198 | cord tissue (Wharton's jelly) | cartilage damage | orthopedics | 2017 | experimental therapy | Poland | 61,5 |
| 199 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 34,1 |
| 200 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 52,9 |
| 201 | cord tissue (Wharton's jelly) | atrophy of the optic nerves | ophthalmology | 2017 | experimental therapy | Poland | 23,9 |
| 202 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 31,6 |
| 203 | cord tissue (Wharton's jelly) | age-related macular degeneration | ophthalmology | 2017 | experimental therapy | Poland | 33,4 |
| 204 | cord tissue (Wharton's jelly) | tetraparesis spastica | neurology | 2017 | experimental therapy | Poland | 29,4 |
| 205 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 24,9 |
| 206 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2017 | experimental therapy | Poland | 10,6 |
| 207 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 30,0 |
| 208 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 56,8 |
| 209 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 65,2 |
| 210 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 45,9 |
| 211 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2017 | experimental therapy | Poland | 28,6 |
| 212 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 44,2 |
| 213 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2017 | experimental therapy | Poland | 41,4 |
| 214 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 25,8 |
| 215 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 75,9 |
| 216 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 23,7 |
| 217 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 43,4 |
| 218 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 39,0 |
| 219 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 51,3 |
| 220 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 39,0 |
| 221 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 42,11 |
| 222 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 30,9 |
| 223 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2017 | experimental therapy | Poland | 12,11 |
| 224 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2017 | experimental therapy | Poland | 8,5 |
| 225 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2017 | experimental therapy | Poland | 58,9 |
| 226 | cord tissue (Wharton's jelly) | cri du chat syndrome | neurology | 2017 | experimental therapy | Poland | 8,6 |
| 227 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 18,7 |
| 228 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 59,8 |
| 229 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 22,1 |
| 230 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2017 | experimental therapy | Poland | 28,11 |
| 231 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2017 | experimental therapy | Poland | 3,1 |
| 232 | cord tissue (Wharton's jelly) | cranium bifidum | neurology | 2017 | experimental therapy | Poland | 5,2 |
| 233 | cord tissue (Wharton's jelly) | transverse myelitis | neurology | 2017 | experimental therapy | Poland | 8,3 |
| 234 | cord tissue (Wharton's jelly) | syringomielia | neurology | 2017 | experimental therapy | Poland | 42,6 |
| 235 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 64,9 |
| 236 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 47,2 |
| 237 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 38,5 |
| 238 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 56,7 |
| 239 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 13,4 |
| 240 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2017 | experimental therapy | Poland | 21,10 |
| 241 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2017 | experimental therapy | Poland | 5,0 |
| 242 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 41,0 |
| 243 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 52,1 |
| 244 | cord tissue (Wharton's jelly) | cerebral palsy, neonatal cerebral leukomalacia | neurology | 2017 | experimental therapy | Poland | 1,9 |
| 245 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 11,11 |
| 246 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 26,10 |
| 247 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 9,1 |
| 248 | cord tissue (Wharton's jelly) | cerebellar syndrome | neurology | 2017 | experimental therapy | Poland | 11,5 |
| 249 | cord tissue (Wharton's jelly) | congenital fiber-type disproportion myopathy | neurology | 2017 | experimental therapy | Poland | 1,10 |
| 250 | cord tissue (Wharton's jelly) | chronic myeloid leukemia | hematology | 2017 | experimental therapy | Poland | 5,11 |
| 251 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 61,5 |
| 252 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 40,11 |
| 253 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 48,1 |
| 254 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 1,11 |
| 255 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 37,11 |
| 256 | cord tissue (Wharton's jelly) | arthrogryposis multiplex congenita | neurology | 2017 | experimental therapy | Poland | 1,7 |
| 257 | cord tissue (Wharton's jelly) | encephalopathy, cerebral palsy | neurology | 2017 | experimental therapy | Poland | 4,4 |
| 258 | cord tissue (Wharton's jelly) | cerebral palsy, epilepsy | neurology | 2017 | experimental therapy | Poland | 5,8 |
| 259 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 6,4 |
| 260 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 15,4 |
| 261 | cord tissue (Wharton's jelly) | traumatic brain injury | neurology | 2017 | experimental therapy | Poland | 9,4 |
| 262 | cord tissue (Wharton's jelly) | no bone adhesion | orthopedics | 2017 | experimental therapy | Poland | 14,1 |
| 263 | cord tissue (Wharton's jelly) | no bone adhesion | orthopedics | 2017 | experimental therapy | Poland | 17,11 |
| 264 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 69,10 |
| 265 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2017 | experimental therapy | Poland | 24,9 |
| 266 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 37,7 |
| 267 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 31,1 |
| 268 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 52,11 |
| 269 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 27,11 |
| 270 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 45,4 |
| 271 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 34,10 |
| 272 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 31,6 |
| 273 | cord tissue (Wharton's jelly) | hydrocephalus, neonatal cerebral leukomalacia | neurology | 2017 | experimental therapy | Poland | 2,3 |
| 274 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 6,3 |
| 275 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 7,11 |
| 276 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2017 | experimental therapy | Poland | 3,5 |
| 277 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2017 | experimental therapy | Poland | 6,3 |
| 278 | cord tissue (Wharton's jelly) | syndrom IFAP | hematology | 2017 | experimental therapy | Poland | 3,5 |
| 279 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 52,0 |
| 280 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2017 | experimental therapy | Poland | 13,0 |
| 281 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2017 | experimental therapy | Poland | 11,10 |
| 282 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 66,11 |
| 283 | cord tissue (Wharton's jelly) | ischemia within the optic nerve | ophthalmology | 2017 | experimental therapy | Poland | 37,11 |
| 284 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 35,1 |
| 285 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 4,11 |
| 286 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 77,2 |
| 287 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 36,11 |
| 288 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 63,11 |
| 289 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 35,6 |
| 290 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 31,9 |
| 291 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 31,9 |
| 292 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 10,2 |
| 293 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 33,5 |
| 294 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 5,7 |
| 295 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 12,5 |
| 296 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 5,9 |
| 297 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 3,3 |
| 298 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2017 | experimental therapy | Poland | 5,0 |
| 299 | cord tissue (Wharton's jelly) | hypoxia-ischemic encephalopathy | neurology | 2017 | experimental therapy | Poland | 1,9 |
| 300 | cord tissue (Wharton's jelly) | Krabbe disease | neurology | 2017 | experimental therapy | Poland | 6,3 |
| 301 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2017 | experimental therapy | Poland | 24,6 |
| 302 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 51,6 |
| 303 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 45,5 |
| 304 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 31,5 |
| 305 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 48,10 |
| 306 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 62,5 |
| 307 | cord tissue (Wharton's jelly) | cerebellar syndrome | neurology | 2017 | experimental therapy | Poland | 60,5 |
| 308 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 6,1 |
| 309 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 4,8 |
| 310 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 6,4 |
| 311 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 6,3 |
| 312 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 46,0 |
| 313 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 49,1 |
| 314 | cord tissue (Wharton's jelly) | condition after encephalitis | neurology | 2017 | experimental therapy | Poland | 19,7 |
| 315 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 35,4 |
| 316 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 1,10 |
| 317 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 6,8 |
| 318 | cord tissue (Wharton's jelly) | encephalopathy, cerebral palsy | neurology | 2017 | experimental therapy | Poland | 1,5 |
| 319 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 7,0 |
| 320 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 13,6 |
| 321 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 6,7 |
| 322 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 32,3 |
| 323 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 46,9 |
| 324 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 54,10 |
| 325 | cord tissue (Wharton's jelly) | dystrophia myotonica | neurology | 2017 | experimental therapy | Poland | 41,11 |
| 326 | cord tissue (Wharton's jelly) | global developmental delay | neurology | 2017 | experimental therapy | Poland | 4,7 |
| 327 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2017 | experimental therapy | Poland | 56,4 |
| 328 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 4,1 |
| 329 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 3,6 |
| 330 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 33,4 |
| 331 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 42,1 |
| 332 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2017 | experimental therapy | Poland | 2,4 |
| 333 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2017 | experimental therapy | Poland | 30,11 |
| 334 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 39,7 |
| 335 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 4,8 |
| 336 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 8,2 |
| 337 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 3,4 |
| 338 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 2,11 |
| 339 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2017 | experimental therapy | Poland | 7,9 |
| 340 | cord tissue (Wharton's jelly) | arthrogryposis multiplex congenita | neurology | 2017 | experimental therapy | Poland | 3,5 |
| 341 | cord tissue (Wharton's jelly) | dystrophia myotonica | neurology | 2017 | experimental therapy | Poland | 3,2 |
| 342 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 63,2 |
| 343 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 76,10 |
| 344 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /BMD | neurology | 2017 | experimental therapy | Poland | 23,9 |
| 345 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 3,7 |
| 346 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 43,8 |
| 347 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2017 | experimental therapy | Poland | 74,5 |
| 348 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 64,7 |
| 349 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 51,6 |
| 350 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 70,11 |
| 351 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 65,1 |
| 352 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2017 | experimental therapy | Poland | 5,5 |
| 353 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 8,4 |
| 354 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 15,1 |
| 355 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 5,8 |
| 356 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 51,3 |
| 357 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 12,10 |
| 358 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 26,9 |
| 359 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 18,4 |
| 360 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 10,8 |
| 361 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 13,1 |
| 362 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 7,9 |
| 363 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 5,5 |
| 364 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 3,7 |
| 365 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 3,5 |
| 366 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 5,1 |
| 367 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 3,4 |
| 368 | cord tissue (Wharton's jelly) | Devic’s disease | neurology | 2017 | experimental therapy | Poland | 45,2 |
| 369 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 31,3 |
| 370 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 6,10 |
| 371 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 5,3 |
| 372 | cord tissue (Wharton's jelly) | epilepsia, autism | neurology | 2017 | experimental therapy | Poland | 6,0 |
| 373 | cord tissue (Wharton's jelly) | myopathy of congenital fiber type disproportion, damage to the central nervous system | neurology | 2017 | experimental therapy | Poland | 2,2 |
| 374 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 2,7 |
| 375 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 68,1 |
| 376 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 59,3 |
| 377 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 49,1 |
| 378 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 60,1 |
| 379 | cord tissue (Wharton's jelly) | global developmental delay | neurology | 2017 | experimental therapy | Poland | 7,11 |
| 380 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 2,8 |
| 381 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 4,11 |
| 382 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 10,8 |
| 383 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 56,7 |
| 384 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 38,0 |
| 385 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 25,2 |
| 386 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 58,7 |
| 387 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 3,2 |
| 388 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 4,7 |
| 389 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 4,8 |
| 390 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 63,0 |
| 391 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 62,9 |
| 392 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 57,9 |
| 393 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 59,11 |
| 394 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 46,5 |
| 395 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 53,9 |
| 396 | cord tissue (Wharton's jelly) | leukodystrophy | neurology | 2017 | experimental therapy | Poland | 7,1 |
| 397 | cord tissue (Wharton's jelly) | atrophy of the optic nerves | ophthalmology | 2017 | experimental therapy | Poland | 35,5 |
| 398 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2017 | experimental therapy | Poland | 16,4 |
| 399 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | b/d |
| 400 | cord tissue (Wharton's jelly) | tetraparesis | orthopedics | 2017 | experimental therapy | Poland | 27,11 |
| 401 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2017 | experimental therapy | Poland | 8,10 |
| 402 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2017 | experimental therapy | Poland | 9,11 |
| 403 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 4,11 |
| 404 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 15,3 |
| 405 | cord tissue (Wharton's jelly) | cerebral palsy, epilepsy | neurology | 2017 | experimental therapy | Poland | 3,6 |
| 406 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 13,6 |
| 407 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 2,4 |
| 408 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 55,2 |
| 409 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 53,10 |
| 410 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | b/d |
| 411 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 3,3 |
| 412 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 2,3 |
| 413 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 4,2 |
| 414 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 27,3 |
| 415 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 3,0 |
| 416 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 4,9 |
| 417 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 47,6 |
| 418 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 65,4 |
| 419 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 2,3 |
| 420 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 54,6 |
| 421 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 77,5 |
| 422 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 30,6 |
| 423 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 78,6 |
| 424 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 33,8 |
| 425 | cord tissue (Wharton's jelly) | condition after myelitis | neurology | 2017 | experimental therapy | Poland | 34,11 |
| 426 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 43,11 |
| 427 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 22,4 |
| 428 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2017 | experimental therapy | Poland | 9,10 |
| 429 | cord tissue (Wharton's jelly) | delayed psychomotor development, epilepsia | neurology | 2017 | experimental therapy | Poland | 11,8 |
| 430 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 18,5 |
| 431 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 7,8 |
| 432 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 6,2 |
| 433 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 10,0 |
| 434 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2017 | experimental therapy | Poland | 1,6 |
| 435 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 32,9 |
| 436 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 4,6 |
| 437 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 1,11 |
| 438 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 22,10 |
| 439 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 44,0 |
| 440 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 78,7 |
| 441 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2017 | experimental therapy | Poland | 37,8 |
| 442 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 3,4 |
| 443 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2017 | experimental therapy | Poland | 12,11 |
| 444 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 61,3 |
| 445 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2017 | experimental therapy | Poland | 65,6 |
| 446 | cord tissue (Wharton's jelly) | hypoxia-ischemic encephalopathy | neurology | 2017 | experimental therapy | Poland | 1,10 |
| 447 | cord tissue (Wharton's jelly) | tetraparesis spastica, epilepsia | neurology | 2017 | experimental therapy | Poland | 2,8 |
| 448 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 5,10 |
| 449 | cord tissue (Wharton's jelly) | spinal cord injury, tetraparesis | orthopedics | 2017 | experimental therapy | Poland | 42,9 |
| 450 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 4,2 |
| 451 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 11,10 |
| 452 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 24,8 |
| 453 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 38,4 |
| 454 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2017 | experimental therapy | Poland | 14,5 |
| 455 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 8,1 |
| 456 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 12,2 |
| 457 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2017 | experimental therapy | Poland | 66,8 |
| 458 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 85,7 |
| 459 | cord tissue (Wharton's jelly) | other specific disorders of the central nervous system | neurology | 2017 | experimental therapy | Poland | 2,1 |
| 460 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 60,1 |
| 461 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 28,7 |
| 462 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 1,6 |
| 463 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 8,0 |
| 464 | cord tissue (Wharton's jelly) | cerebellar syndrome | neurology | 2017 | experimental therapy | Poland | 52,6 |
| 465 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2017 | experimental therapy | Poland | 35,9 |
| 466 | cord tissue (Wharton's jelly) | cerebellar syndrome | neurology | 2017 | experimental therapy | Poland | 60,11 |
| 467 | cord tissue (Wharton's jelly) | congenital malformations of the nervous system, unspecified | neurology | 2017 | experimental therapy | Poland | 8,2 |
| 468 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 10,3 |
| 469 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 2,8 |
| 470 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2017 | experimental therapy | Poland | 24,6 |
| 471 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 29,8 |
| 472 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 78,5 |
| 473 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 61,7 |
| 474 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 65,10 |
| 475 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 10,9 |
| 476 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 17,0 |
| 477 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 5,6 |
| 478 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 52,8 |
| 479 | cord tissue (Wharton's jelly) | cerebral palsy, epilepsy | neurology | 2017 | experimental therapy | Poland | 2,1 |
| 480 | cord tissue (Wharton's jelly) | autism, encephalopathy | neurology | 2017 | experimental therapy | Poland | 7,11 |
| 481 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 5,9 |
| 482 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 5,10 |
| 483 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 69,2 |
| 484 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2017 | experimental therapy | Poland | 64,3 |
| 485 | cord tissue (Wharton's jelly) | cartilage damage | orthopedics | 2017 | experimental therapy | Poland | 46,10 |
| 486 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 37,1 |
| 487 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 43,10 |
| 488 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 59,0 |
| 489 | cord tissue (Wharton's jelly) | cerebellar syndrome | neurology | 2017 | experimental therapy | Poland | 46,5 |
| 490 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 2,8 |
| 491 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 6,5 |
| 492 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 54,2 |
| 493 | cord tissue (Wharton's jelly) | other specific disorders of the central nervous system | neurology | 2017 | experimental therapy | Poland | 2,4 |
| 494 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 8,6 |
| 495 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2017 | experimental therapy | Poland | 7,4 |
| 496 | cord tissue (Wharton's jelly) | cerebellar ataxia | neurology | 2017 | experimental therapy | Poland | 33,0 |
| 497 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 36,9 |
| 498 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 45,3 |
| 499 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 6,2 |
| 500 | cord tissue (Wharton's jelly) | autism | neurology | 2017 | experimental therapy | Poland | 7,8 |
| 501 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 1,6 |
| 502 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2017 | experimental therapy | Poland | 7,6 |
| 503 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2017 | experimental therapy | Poland | 66,10 |
| 504 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2017 | experimental therapy | Poland | 48,8 |
| 505 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2017 | experimental therapy | Poland | 8,3 |
| 506 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2017 | experimental therapy | Poland | 15,9 |
| 507 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 14,4 |
| 508 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 48,2 |
| 509 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 2,5 |
| 510 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2017 | experimental therapy | Poland | 6,2 |
| 511 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2017 | experimental therapy | Poland | 7,11 |
| 512 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2017 | experimental therapy | Poland | 9/12 |
| 513 | cord tissue (Wharton's jelly) | moyamoya disease | neurology | 2017 | experimental therapy | Poland | 17,7 |
| 514 | cord tissue (Wharton's jelly) | anterior ischemic optic neuropathy | ophthalmology | 2017 | experimental therapy | Poland | 67,7 |
| 515 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2017 | experimental therapy | Poland | 57,1 |
| 516 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2017 | experimental therapy | Poland | 71,8 |
| 517 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 10,11 |
| 518 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 44,5 |
| 519 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 60,8 |
| 520 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 32,2 |
| 521 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2016 | experimental therapy | Poland | 64 |
| 522 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2016 | experimental therapy | Poland | 62,5 |
| 523 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 18,4 |
| 524 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2016 | experimental therapy | Poland | 48,8 |
| 525 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 10,3 |
| 526 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 35,3 |
| 527 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 53,7 |
| 528 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 12,2 |
| 529 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2016 | experimental therapy | Poland | 3,10 |
| 530 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2016 | experimental therapy | Poland | 14 |
| 531 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2016 | experimental therapy | Poland | 6 |
| 532 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2016 | experimental therapy | Poland | 65,8 |
| 533 | cord tissue (Wharton's jelly) | leukodystrophy | neurology | 2016 | experimental therapy | Poland | 2,9 |
| 534 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 59,4 |
| 535 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 6 |
| 536 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 2,11 |
| 537 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 12,11 |
| 538 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 9,7 |
| 539 | cord tissue (Wharton's jelly) | atrophy of the optic nerves | ophthalmology | 2016 | experimental therapy | Poland | 20,3 |
| 540 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2016 | experimental therapy | Poland | 53 |
| 541 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 33,5 |
| 542 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 22,2 |
| 543 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 10,3 |
| 544 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 8,5 |
| 545 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 29,11 |
| 546 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 33,4 |
| 547 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 37,4 |
| 548 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 39,3 |
| 549 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 7,11 |
| 550 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 28 |
| 551 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2016 | experimental therapy | Poland | 69,6 |
| 552 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 33,11 |
| 553 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 20,7 |
| 554 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 24,5 |
| 555 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 25,6 |
| 556 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 8,5 |
| 557 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 39,10 |
| 558 | cord tissue (Wharton's jelly) | patella cartilage damage | orthopedics | 2016 | experimental therapy | Poland | 60,10 |
| 559 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 6,9 |
| 560 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 44,8 |
| 561 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 25,4 |
| 562 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 10,10 |
| 563 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 63,2 |
| 564 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 54,11 |
| 565 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 53,9 |
| 566 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 46,9 |
| 567 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 58 |
| 568 | cord tissue (Wharton's jelly) | chronic graft versus host disease | hematology | 2016 | experimental therapy | Poland | 19,2 |
| 569 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 55 |
| 570 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 58,1 |
| 571 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 61,7 |
| 572 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 52,6 |
| 573 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 59,11 |
| 574 | cord tissue (Wharton's jelly) | tetraparesis spastica | orthopedics | 2016 | experimental therapy | Poland | 28,8 |
| 575 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 60,9 |
| 576 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2016 | experimental therapy | Poland | 34,9 |
| 577 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2016 | experimental therapy | Poland | 69,3 |
| 578 | cord tissue (Wharton's jelly) | tetraparesis spastica | orthopedics | 2016 | experimental therapy | Poland | 47,9 |
| 579 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 18,8 |
| 580 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 2,9 |
| 581 | cord tissue (Wharton's jelly) | traumatic brain injury | neurology | 2016 | experimental therapy | Poland | 54,9 |
| 582 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2016 | experimental therapy | Poland | 19,5 |
| 583 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 59 |
| 584 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 66,9 |
| 585 | cord tissue (Wharton's jelly) | tetraparesis | orthopedics | 2016 | experimental therapy | Poland | 27,9 |
| 586 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2016 | experimental therapy | Poland | 14,9 |
| 587 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 42,7 |
| 588 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2016 | experimental therapy | Poland | 60,5 |
| 589 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 6,2 |
| 590 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 11,3 |
| 591 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 9,11 |
| 592 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2016 | experimental therapy | Poland | 49,8 |
| 593 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2016 | experimental therapy | Poland | 69,9 |
| 594 | cord tissue (Wharton's jelly) | optic atrophy | ophthalmology | 2016 | experimental therapy | Poland | 69,1 |
| 595 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2016 | experimental therapy | Poland | 13,11 |
| 596 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 45,1 |
| 597 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 53,4 |
| 598 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 36,1 |
| 599 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 59, 1 |
| 600 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 66,2 |
| 601 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 49,7 |
| 602 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 55,1 |
| 603 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 46,1 |
| 604 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 72,4 |
| 605 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 54,3 |
| 606 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 56,1 |
| 607 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 61,8 |
| 608 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 64,7 |
| 609 | cord tissue (Wharton's jelly) | malformation syndrome | neurology | 2016 | experimental therapy | Poland | 3,5 |
| 610 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 64,2 |
| 611 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 38 |
| 612 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 6,10 |
| 613 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2016 | experimental therapy | Poland | 2,11 |
| 614 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 62,8 |
| 615 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 56,5 |
| 616 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 51,3 |
| 617 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 2,10 |
| 618 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 4,2 |
| 619 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 55,4 |
| 620 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 54,8 |
| 621 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 33,10 |
| 622 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 41,4 |
| 623 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 49,3 |
| 624 | cord tissue (Wharton's jelly) | choroideremia | ophthalmology | 2016 | experimental therapy | Poland | 50,8 |
| 625 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 63,1 |
| 626 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 7,4 |
| 627 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 60,4 |
| 628 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 73,7 |
| 629 | cord tissue (Wharton's jelly) | leukodystrophy | neurology | 2016 | experimental therapy | Poland | 2,11 |
| 630 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 61,6 |
| 631 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 48,3 |
| 632 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 32,7 |
| 633 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2016 | experimental therapy | Poland | 3,11 |
| 634 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 61,11 |
| 635 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 45,8 |
| 636 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 61,4 |
| 637 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 79,2 |
| 638 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 72,6 |
| 639 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 48,4 |
| 640 | cord tissue (Wharton's jelly) | adrenoleukodystrophy | neurology | 2016 | experimental therapy | Poland | 6,11 |
| 641 | cord tissue (Wharton's jelly) | adrenoleukodystrophy | neurology | 2016 | experimental therapy | Poland | 9,7 |
| 642 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 54,2 |
| 643 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 50,9 |
| 644 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 22 |
| 645 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2016 | experimental therapy | Poland | 14,7 |
| 646 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 55,9 |
| 647 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 62,6 |
| 648 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 58,10 |
| 649 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 12,6 |
| 650 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 66,2 |
| 651 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 55,9 |
| 652 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 49,4 |
| 653 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 55,7 |
| 654 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 58,1 |
| 655 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 4,8 |
| 656 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 1,5 |
| 657 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 3 |
| 658 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 9,9 |
| 659 | cord tissue (Wharton's jelly) | global developmental delay | neurology | 2016 | experimental therapy | Poland | 6,9 |
| 660 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 66,8 |
| 661 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 39,6 |
| 662 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 13,2 |
| 663 | cord tissue (Wharton's jelly) | developmental delay | neurology | 2016 | experimental therapy | Poland | 7,4 |
| 664 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 7,4 |
| 665 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2016 | experimental therapy | Poland | 66 |
| 666 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 38,1 |
| 667 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 8,4 |
| 668 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 3 |
| 669 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2016 | experimental therapy | Poland | 79,8 |
| 670 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2016 | experimental therapy | Poland | 54,3 |
| 671 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2016 | experimental therapy | Poland | 14,4 |
| 672 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 47,11 |
| 673 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 49,3 |
| 674 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 61,2 |
| 675 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 23,6 |
| 676 | cord tissue (Wharton's jelly) | age-related macular degeneration | ophthalmology | 2016 | experimental therapy | Poland | 86,5 |
| 677 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 54,6 |
| 678 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 68,5 |
| 679 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 13,7 |
| 680 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 2,2 |
| 681 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 5,0 |
| 682 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 12,11 |
| 683 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 12,3 |
| 684 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 1,3 |
| 685 | cord tissue (Wharton's jelly) | developmental delay | neurology | 2016 | experimental therapy | Poland | 2,7 |
| 686 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2016 | experimental therapy | Poland | 3,3 |
| 687 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 59,6 |
| 688 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2016 | experimental therapy | Poland | 34,2 |
| 689 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 30,3 |
| 690 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2016 | experimental therapy | Poland | 17,10 |
| 691 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 37,11 |
| 692 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 31,9 |
| 693 | cord tissue (Wharton's jelly) | ataxia hereditaria | neurology | 2016 | experimental therapy | Poland | 69 |
| 694 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 31,9 |
| 695 | cord tissue (Wharton's jelly) | no data | ophthalmology | 2016 | experimental therapy | Poland | 66,1 |
| 696 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 53,4 |
| 697 | cord tissue (Wharton's jelly) | patella cartilage damage | orthopedics | 2016 | experimental therapy | Poland | 60,8 |
| 698 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 10,8 |
| 699 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2016 | experimental therapy | Poland | 3 |
| 700 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 2,11 |
| 701 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2016 | experimental therapy | Poland | 4,3 |
| 702 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | no data |
| 703 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 59,4 |
| 704 | cord tissue (Wharton's jelly) | atrophy of the optic nerves | ophthalmology | 2016 | experimental therapy | Poland | 20,11 |
| 705 | cord tissue (Wharton's jelly) | patella cartilage damage | orthopedics | 2016 | experimental therapy | Poland | 53 |
| 706 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 24,5 |
| 707 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2016 | experimental therapy | Poland | 34, 7 |
| 708 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 32,3 |
| 709 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 65,9 |
| 710 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 52,7 |
| 711 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 71,5 |
| 712 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 60,7 |
| 713 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 1,10 |
| 714 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 7,6 |
| 715 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2016 | experimental therapy | Poland | 1,10 |
| 716 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 29,7 |
| 717 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 68,5 |
| 718 | cord tissue (Wharton's jelly) | chronic graft versus host disease | hematology | 2016 | experimental therapy | Poland | 8/12 |
| 719 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 44,5 |
| 720 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2016 | experimental therapy | Poland | 9,2 |
| 721 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2016 | experimental therapy | Poland | 24,5 |
| 722 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 66,7 |
| 723 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 15,9 |
| 724 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 6,8 |
| 725 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 10,3 |
| 726 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 16,4 |
| 727 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 6 |
| 728 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2016 | experimental therapy | Poland | 41,8 |
| 729 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 51,9 |
| 730 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 49,3 |
| 731 | cord tissue (Wharton's jelly) | autism | neurology | 2016 | experimental therapy | Poland | 20,9 |
| 732 | cord tissue (Wharton's jelly) | fetal alcohol spectrum disorders | neurology | 2016 | experimental therapy | Poland | 5,2 |
| 733 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 13,10 |
| 734 | cord tissue (Wharton's jelly) | tetraparesis spastica | orthopedics | 2016 | experimental therapy | Poland | 58,4 |
| 735 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 68,2 |
| 736 | cord tissue (Wharton's jelly) | chondronecrosis femoral condyle | orthopedics | 2016 | experimental therapy | Poland | 54,11 |
| 737 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 55,4 |
| 738 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 41,2 |
| 739 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 72,1 |
| 740 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 56,8 |
| 741 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 2,11 |
| 742 | cord tissue (Wharton's jelly) | tetraparesis spastica | orthopedics | 2016 | experimental therapy | Poland | 18 |
| 743 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 4,1 |
| 744 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 48,1 |
| 745 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 56,3 |
| 746 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 66,10 |
| 747 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | no data |
| 748 | cord tissue (Wharton's jelly) | gangliosidosis t. 1 | neurology | 2016 | experimental therapy | Poland | 1,4 |
| 749 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2016 | experimental therapy | Poland | 14,9 |
| 750 | cord tissue (Wharton's jelly) | epileptic encephalopathy | neurology | 2016 | experimental therapy | Poland | 3,6 |
| 751 | cord tissue (Wharton's jelly) | polineuropathy | neurology | 2016 | experimental therapy | Poland | 70,8 |
| 752 | cord tissue (Wharton's jelly) | diffuse cartilage damage left medial compartment of the knee | orthopedics | 2016 | experimental therapy | Poland | 50,5 |
| 753 | cord tissue (Wharton's jelly) | Stargardt's disease | ophthalmology | 2016 | experimental therapy | Poland | 37,7 |
| 754 | cord tissue (Wharton's jelly) | myopia, hyperopia, astigmatism, abnormal refraction and accommodation, optic atrophy | ophthalmology | 2016 | experimental therapy | Poland | 37,1 |
| 755 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2016 | experimental therapy | Poland | 33,5 |
| 756 | cord tissue (Wharton's jelly) | epilepsia | neurology | 2016 | experimental therapy | Poland | 16,2 |
| 757 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 3,7 |
| 758 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 17,9 |
| 759 | cord tissue (Wharton's jelly) | injuries to the spinal nerves | neurology | 2016 | experimental therapy | Poland | 5/12 |
| 760 | cord tissue (Wharton's jelly) | cartilage damage | orthopedics | 2016 | experimental therapy | Poland | 57,6 |
| 761 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2016 | experimental therapy | Poland | 4,8 |
| 762 | cord tissue (Wharton's jelly) | limb-girdle muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 44,7 |
| 763 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /DMD | neurology | 2016 | experimental therapy | Poland | 10 |
| 764 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2016 | experimental therapy | Poland | 4,4 |
| 765 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2016 | experimental therapy | Poland | 4,9 |
| 766 | cord tissue (Wharton's jelly) | cerebellar syndrome | neurology | 2016 | experimental therapy | Poland | 28,6 |
| 767 | cord tissue (Wharton's jelly) | neurodevelopmental disorders | neurology | 2016 | experimental therapy | Poland | 4,5 |
| 768 | cord tissue (Wharton's jelly) | tetraparesis | orthopedics | 2016 | experimental therapy | Poland | 27,2 |
| 769 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 61,2 |
| 770 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2016 | experimental therapy | Poland | 44,8 |
| 771 | cord tissue (Wharton's jelly) | degeneration of the cartilage of the knee joint | orthopedics | 2016 | experimental therapy | Poland | 54,3 |
| 772 | cord tissue (Wharton's jelly) | dystrophia progressiva pseudohypertrophica /BMD | neurology | 2016 | experimental therapy | Poland | 19,2 |
| 773 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 15,0 |
| 774 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 31,11 |
| 775 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2016 | experimental therapy | Poland | 33,4 |
| 776 | cord tissue (Wharton's jelly) | endometrial atrophy | ginecology | 2016 | experimental therapy | Poland | 37,3 |
| 777 | cord tissue (Wharton's jelly) | endometrial atrophy | ginecology | 2016 | experimental therapy | Poland | 39,1 |
| 778 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2016 | experimental therapy | Poland | 38,4 |
| 779 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2016 | experimental therapy | Poland | 44,5 |
| 780 | cord tissue (Wharton's jelly) | meniscus damage | orthopedics | 2016 | experimental therapy | Poland | 35,5 |
| 781 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 60,8 |
| 782 | cord tissue (Wharton's jelly) | premature ovarian failure | ginecology | 2016 | experimental therapy | Poland | 23,4 |
| 783 | cord tissue (Wharton's jelly) | premature ovarian failure | ginecology | 2016 | experimental therapy | Poland | 34,9 |
| 784 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2016 | experimental therapy | Poland | 55,5 |
| 785 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2015 | experimental therapy | Poland | 1,4 |
| 786 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 5,4 |
| 787 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2015 | experimental therapy | Poland | 23,2 |
| 788 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 61,6 |
| 789 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 61 |
| 790 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 56 |
| 791 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 51 |
| 792 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 65 |
| 793 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 60 |
| 794 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 52 |
| 795 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 3,8 |
| 796 | cord tissue (Wharton's jelly) | decerebration rigidity | neurology | 2015 | experimental therapy | Poland | 9,6 |
| 797 | cord tissue (Wharton's jelly) | bilateral blindness | phthalmology | 2015 | experimental therapy | Poland | 36,10 |
| 798 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2015 | experimental therapy | Poland | 11/12 |
| 799 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 7,1 |
| 800 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 15,8 |
| 801 | cord tissue (Wharton's jelly) | ceroid lipofuscinosis | neurology | 2015 | experimental therapy | Poland | 5,1 |
| 802 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2015 | experimental therapy | Poland | 14,5 |
| 803 | cord tissue (Wharton's jelly) | ceroid lipofuscinosis | neurology | 2015 | experimental therapy | Poland | 7,10 |
| 804 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 3 |
| 805 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 7,1 |
| 806 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 13,1 |
| 807 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2015 | experimental therapy | Poland | 2,4 |
| 808 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 59,4 |
| 809 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 31,2 |
| 810 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 5,1 |
| 811 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 12,5 |
| 812 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 8,11 |
| 813 | cord tissue (Wharton's jelly) | delayed psychomotor development, deafness | neurology | 2015 | experimental therapy | Poland | 3,3 |
| 814 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 61,5 |
| 815 | cord tissue (Wharton's jelly) | traumatic encephalopathy | neurology | 2015 | experimental therapy | Poland | 20,11 |
| 816 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 18,8 |
| 817 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 2,7 |
| 818 | cord tissue (Wharton's jelly) | adrenoleukodystrophy, encephalopathy | neurology | 2015 | experimental therapy | Poland | 23 |
| 819 | cord tissue (Wharton's jelly) | adrenoleukodystrophy | neurology | 2015 | experimental therapy | Poland | 11,11 |
| 820 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 40 |
| 821 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 26,1 |
| 822 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 37,1 |
| 823 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 58 |
| 824 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2015 | experimental therapy | Poland | 35,6 |
| 825 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2015 | experimental therapy | Poland | 11/12 |
| 826 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2015 | experimental therapy | Poland | 44,6 |
| 827 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2015 | experimental therapy | Poland | 15,8 |
| 828 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 61,6 |
| 829 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2015 | experimental therapy | Poland | 66,2 |
| 830 | cord tissue (Wharton's jelly) | iatrogenic spinal cord injury | neurology | 2015 | experimental therapy | Poland | 17,2 |
| 831 | cord tissue (Wharton's jelly) | optic neuropathy | ophthalmology | 2015 | experimental therapy | Poland | 45,10 |
| 832 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 62 |
| 833 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2015 | experimental therapy | Poland | 51,5 |
| 834 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 12,10 |
| 835 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 26,5 |
| 836 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 27 |
| 837 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 4,10 |
| 838 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 6,1 |
| 839 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 4,6 |
| 840 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 63,11 |
| 841 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 32,10 |
| 842 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 22 |
| 843 | cord tissue (Wharton's jelly) | sclerosis multiplex | neurology | 2015 | experimental therapy | Poland | 33,3 |
| 844 | cord tissue (Wharton's jelly) | delayed psychomotor development | neurology | 2015 | experimental therapy | Poland | 3,6 |
| 845 | cord tissue (Wharton's jelly) | spina bifida | neurology | 2015 | experimental therapy | Poland | 2 |
| 846 | cord tissue (Wharton's jelly) | cerebellar ataxia | neurology | 2015 | experimental therapy | Poland | 18,7 |
| 847 | cord tissue (Wharton's jelly) | spinocerebellar ataxia | neurology | 2015 | experimental therapy | Poland | 24,3 |
| 848 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 67,6 |
| 849 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 5,6 |
| 850 | cord tissue (Wharton's jelly) | polineuropathy | neurology | 2015 | experimental therapy | Poland | 74,2 |
| 851 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 37,6 |
| 852 | cord tissue (Wharton's jelly) | stroke | neurology | 2015 | experimental therapy | Poland | 62,8 |
| 853 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 58,10 |
| 854 | cord tissue (Wharton's jelly) | facio-scapulo-humeral muscular dystrophy | neurology | 2015 | experimental therapy | Poland | 30,1 |
| 855 | cord tissue (Wharton's jelly) | chronic graft versus host disease | hematology | 2015 | experimental therapy | Poland | 10 |
| 856 | cord tissue (Wharton's jelly) | severe developmental delay | neurology | 2015 | experimental therapy | Poland | 1,1 |
| 857 | cord tissue (Wharton's jelly) | spinal muscular atrophy | neurology | 2015 | experimental therapy | Poland | 26,2 |
| 858 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 46,2 |
| 859 | cord tissue (Wharton's jelly) | autism | neurology | 2015 | experimental therapy | Poland | 8,7 |
| 860 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2015 | experimental therapy | Poland | 8/12 |
| 861 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2015 | experimental therapy | Poland | 6,6 |
| 862 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 48,7 |
| 863 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 21,4 |
| 864 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 9,9 |
| 865 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2015 | experimental therapy | Poland | 13,4 |
| 866 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 61,3 |
| 867 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2015 | experimental therapy | Poland | 54 |
| 868 | cord tissue (Wharton's jelly) | intracranial injury | neurology | 2015 | experimental therapy | Poland | 24,3 |
| 869 | cord tissue (Wharton's jelly) | stroke | neurology | 2015 | experimental therapy | Poland | 54,9 |
| 870 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 24,7 |
| 871 | cord tissue (Wharton's jelly) | gonarthrosis | orthopedics | 2015 | experimental therapy | Poland | 65,9 |
| 872 | cord tissue (Wharton's jelly) | leukodystrophy | neurology | 2015 | experimental therapy | Poland | 18,8 |
| 873 | cord tissue (Wharton's jelly) | spinal cord injury | orthopedics | 2015 | experimental therapy | Poland | 34,4 |
| 874 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 1,6 |
| 875 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 14,10 |
| 876 | cord tissue (Wharton's jelly) | anterior ischemic optic neuropathy | ophthalmology | 2015 | experimental therapy | Poland | 54,10 |
| 877 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2015 | experimental therapy | Poland | 16,9 |
| 878 | cord tissue (Wharton's jelly) | retinitis pigmentosa | ophthalmology | 2015 | experimental therapy | Poland | 34,5 |
| 879 | cord tissue (Wharton's jelly) | cerebellar ataxia | neurology | 2015 | experimental therapy | Poland | 26,1 |
| 880 | cord tissue (Wharton's jelly) | encephalopathy | neurology | 2015 | experimental therapy | Poland | 11,2 |
| 881 | cord tissue (Wharton's jelly) | adrenoleukodystrophy, encephalopathy | neurology | 2015 | experimental therapy | Poland | 8,4 |
| 882 | cord tissue (Wharton's jelly) | neuropathy | neurology | 2014 | experimental therapy | Poland | 23,6 |
| 883 | cord tissue (Wharton's jelly) | autism | neurology | 2014 | experimental therapy | Poland | 12,6 |
| 884 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2014 | experimental therapy | Poland | 6 |
| 885 | cord tissue (Wharton's jelly) | central motor coordination impairment after hypoxic ischaemia lesion at birth | neurology | 2014 | experimental therapy | Poland | 2,1 |
| 886 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2014 | experimental therapy | Poland | 60,10 |
| 887 | cord tissue (Wharton's jelly) | amyotrophic lateral sclerosis | neurology | 2014 | experimental therapy | Poland | 24,1 |
| 888 | cord tissue (Wharton's jelly) | autism | neurology | 2014 | experimental therapy | Poland | 8,3 |
| 889 | cord tissue (Wharton's jelly) | muscular dystrophy | neurology | 2014 | experimental therapy | Poland | 6 |
| 890 | cord tissue (Wharton's jelly) | birth asphyxia, retinopathy | neurology | 2014 | experimental therapy | Poland | 11/12 |
| 891 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2014 | experimental therapy | Poland | 4,10 |
| 892 | cord tissue (Wharton's jelly) | cerebral palsy | neurology | 2014 | experimental therapy | Poland | 15,10 |
| 893 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2013 | experimental therapy | Poland | 18,9 |
| 894 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2013 | experimental therapy | Poland | 2,11 |
| 895 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2013 | experimental therapy | Poland | 3,5 |
| 896 | cord tissue (Wharton's jelly) | acute myeloid leukemia | hematology | 2013 | experimental therapy | Poland | 3,5 |
| 897 | cord tissue (Wharton's jelly) | chronic graft versus host disease | hematology | 2013 | experimental therapy | Poland | 18,8 |
| 898 | cord tissue (Wharton's jelly) | chronic graft versus host disease | hematology | 2013 | experimental therapy | Poland | 17,5 |
| 899 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2012 | experimental therapy | Poland | 19,7 |
| 900 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2012 | experimental therapy | Poland | 7,1 |
| 901 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2012 | experimental therapy | Poland | 4,3 |
| 902 | cord tissue (Wharton's jelly) | acute graft versus host disease | hematology | 2011 | experimental therapy | Poland | 17,2 |
| 903 | bone marrow | myelodysplastic syndrome | hematology | 2018 | standard therapy | Italy | 4 |
| 904 | bone marrow | chronic granulomatous disease | hematology | 2018 | standard therapy | Switzerland | 3 |
| 905 | bone marrow | juvenile myelomonocytic leukemia | hematology | 2018 | standard therapy | Hungary | 11 |
| 906 | bone marrow | Hodgkin’s lymphoma | hematology | 2018 | standard therapy | USA | 31 |
| 907 | bone marrow | bilineal leukemia -acute lymphoblastic leukemia, acute myelogenous leukemia | hematology | 2018 | standard therapy | Belarus | 2 |
| 908 | bone marrow | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Italy | 3/4 |
| 909 | bone marrow | acute myelogenous leukemia | hematology | 2018 | standard therapy | Switzerland | 67 |
| 910 | bone marrow | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Brazil | 3 |
| 911 | bone marrow | no data | hematology | 2018 | standard therapy | Spain | 48 |
| 912 | bone marrow | no data | hematology | 2018 | standard therapy | Germany | 16 |
| 913 | bone marrow | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Poland | 12 |
| 914 | bone marrow | acute myelogenous leukemia | hematology | 2018 | standard therapy | Italy | 36 |
| 915 | bone marrow | thalassemia major | hematology | 2018 | standard therapy | Sweden | 14 |
| 916 | bone marrow | severe aplastic anaemia | hematology | 2018 | standard therapy | USA | 19 |
| 917 | bone marrow | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | USA | 50 |
| 918 | bone marrow | diffuse large B-cell lymphoma | hematology | 2018 | standard therapy | Germany | 68 |
| 919 | bone marrow | severe combined immunodeficiency | hematology | 2018 | standard therapy | Israel | 2 |
| 920 | bone marrow | severe aplastic anaemia | hematology | 2018 | standard therapy | Italy | 14 |
| 921 | bone marrow | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | USA | 11 |
| 922 | bone marrow | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Argentina | 14 |
| 923 | bone marrow | chronic granulomatous disease | hematology | 2018 | standard therapy | USA | 2 |
| 924 | bone marrow | severe combined immunodeficiency | hematology | 2018 | standard therapy | USA | 1 |
| 925 | bone marrow | acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 20 |
| 926 | bone marrow | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Canada | 8 |
| 927 | bone marrow | acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 1 |
| 928 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 6 |
| 929 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 76 |
| 930 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Turkey | 22 |
| 931 | bone marrow | chronic granulomatous disease | hematology | 2017 | standard therapy | Poland | 2 |
| 932 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 65 |
| 933 | bone marrow | myelodysplastic syndrome | hematology | 2017 | standard therapy | Italy | 60 |
| 934 | bone marrow | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 61 |
| 935 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Russia | 30 |
| 936 | bone marrow | chronic granulomatous disease | hematology | 2017 | standard therapy | Poland | 4 |
| 937 | bone marrow | leukemia | hematology | 2017 | standard therapy | USA | 40 |
| 938 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | United Kingdom | 10 |
| 939 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Hungary | 14 |
| 940 | bone marrow | severe combined immunodeficiency | hematology | 2017 | standard therapy | Turkey | 6 |
| 941 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 55 |
| 942 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 67 |
| 943 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 16 |
| 944 | bone marrow | severe combined immunodeficiency | hematology | 2017 | standard therapy | Lithuania | 1 |
| 945 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 13 |
| 946 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Italy | 38 |
| 947 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | United Kingdom | 9 |
| 948 | bone marrow | severe combined immunodeficiency | hematology | 2017 | standard therapy | Canada | 1 |
| 949 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Russia | 59 |
| 950 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 21 |
| 951 | bone marrow | severe combined immunodeficiency | hematology | 2017 | standard therapy | Turkey | 2 |
| 952 | bone marrow | hyper IgM syndrome | hematology | 2017 | standard therapy | Finland | 2 |
| 953 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Austria | 3 |
| 954 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Russia | 1 |
| 955 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 59 |
| 956 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 57 |
| 957 | bone marrow | pure red cell aplasia | hematology | 2017 | standard therapy | USA | 5 |
| 958 | bone marrow | thalassemia major | hematology | 2017 | standard therapy | Turkey | 11 |
| 959 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 10 |
| 960 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Czech Republic | 68 |
| 961 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 60 |
| 962 | bone marrow | Fanconi anaemia | hematology | 2017 | standard therapy | Russia | 10 |
| 963 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 10 |
| 964 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 17 |
| 965 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 51 |
| 966 | bone marrow | juvenile myelomonocytic leukemia | hematology | 2017 | standard therapy | Finland | 1 |
| 967 | bone marrow | acute megakaryocytic leukemia | hematology | 2017 | standard therapy | Spain | 2 |
| 968 | bone marrow | chronic myeloid leukemia | hematology | 2017 | standard therapy | USA | 51 |
| 969 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 56 |
| 970 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Russia | 54 |
| 971 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | France | 24 |
| 972 | bone marrow | severe combined immunodeficiency | hematology | 2017 | standard therapy | Poland | 1 |
| 973 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | United Kingdom | 8 |
| 974 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 9 |
| 975 | bone marrow | no data | hematology | 2017 | standard therapy | France | 32 |
| 976 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Brazil | 14 |
| 977 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Italy | 4 |
| 978 | bone marrow | Wiskott-Aldrich syndrome | hematology | 2017 | standard therapy | Iran | 2 |
| 979 | bone marrow | T-cell leukemia/lymphoma | hematology | 2017 | standard therapy | Iran | 18 |
| 980 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Italy | 7 |
| 981 | bone marrow | myeloma multiplex | hematology | 2017 | standard therapy | Canada | 50 |
| 982 | bone marrow | other combined immunodeficiency | hematology | 2017 | standard therapy | USA | 11 |
| 983 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Italy | 2 |
| 984 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | France | 12 |
| 985 | bone marrow | myelodysplastic syndrome | hematology | 2017 | standard therapy | Norway | 2 |
| 986 | bone marrow | Nijmegen breakage syndrome | hematology | 2017 | standard therapy | Poland | 8 |
| 987 | bone marrow | secondary acute myelogenous leukemiaafter Ewing sarcoma | hematology | 2017 | standard therapy | Germany | 16 |
| 988 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | India | 7 |
| 989 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 18 |
| 990 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | France | 2 |
| 991 | bone marrow | severe combined immunodeficiency | hematology | 2017 | standard therapy | Turkey | 8 |
| 992 | bone marrow | Fanconi anaemia | hematology | 2017 | standard therapy | Belarus | 10 |
| 993 | bone marrow | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Hungary | 7 |
| 994 | bone marrow | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 19 |
| 995 | bone marrow | primary Immunodeficiency, Nijmegen breakage syndrome | hematology | 2017 | standard therapy | Belarus | 6 |
| 996 | bone marrow | osteopetrosis | metabolic | 2016 | standard therapy | Russia | 6 |
| 997 | bone marrow | severe combined immunodeficiency | hematology | 2016 | standard therapy | Romania | 2 |
| 998 | bone marrow | T-cell acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Italy | 4 |
| 999 | bone marrow | no data | n/a | 2016 | standard therapy | Italy | 3 |
| 1000 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 64 |
| 1001 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Italy | 9 |
| 1002 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Spain | 55 |
| 1003 | bone marrow | Fanconi anaemia | hematology | 2016 | standard therapy | Estonia | 7 |
| 1004 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Italy | 6 |
| 1005 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 64 |
| 1006 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Italy | 14 |
| 1007 | bone marrow | biphenotypic leukemia | hematology | 2016 | standard therapy | Brazil | 27 |
| 1008 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Germany | 7 |
| 1009 | bone marrow | osteopetrosis | metabolic | 2016 | standard therapy | Germany | 1 |
| 1010 | bone marrow | severe aplastic anaemia | hematology | 2016 | standard therapy | France | 9 |
| 1011 | bone marrow | no data | n/a | 2016 | standard therapy | Poland | 7 |
| 1012 | bone marrow | Hurler syndrome | metabolic | 2016 | standard therapy | United Kingdom | 2 |
| 1013 | bone marrow | severe combined immunodeficiency | hematology | 2016 | standard therapy | Turkey | 4 |
| 1014 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Canada | 11 |
| 1015 | bone marrow | myelofibrosis | hematology | 2016 | standard therapy | Germany | 31 |
| 1016 | bone marrow | DiGeorge syndrome | hematology | 2016 | standard therapy | Netherlands | 24 |
| 1017 | bone marrow | Hodgkin’s lymphoma | hematology | 2016 | standard therapy | Italy | 17 |
| 1018 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Belarus | 12 |
| 1019 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Belarus | 18 |
| 1020 | bone marrow | evere combined immunodeficiency | hematology | 2016 | standard therapy | Poland | 7/12 |
| 1021 | bone marrow | severe aplastic anaemia | hematology | 2016 | standard therapy | France | 9 |
| 1022 | bone marrow | severe aplastic anaemia / paroxymal nocturnal haemoglobinuria | hematology | 2016 | standard therapy | Poland | 17 |
| 1023 | bone marrow | myelodysplastic syndrome | hematology | 2016 | standard therapy | Hungary | 1 |
| 1024 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 67 |
| 1025 | bone marrow | myelodysplastic syndrome | hematology | 2016 | standard therapy | Spain | 56 |
| 1026 | bone marrow | Fanconi anaemia | hematology | 2016 | standard therapy | Netherlands | 41 |
| 1027 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | France | 5 |
| 1028 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | United Kingdom | 29 |
| 1029 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Belarus | 25 |
| 1030 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | New Zealand | 1 |
| 1031 | bone marrow | severe combined immunodeficiency | hematology | 2016 | standard therapy | Germany | 12 |
| 1032 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 5 |
| 1033 | bone marrow | no data | n/a | 2016 | standard therapy | Poland | 33 |
| 1034 | bone marrow | non-Hodgkin lymphoma | hematology | 2016 | standard therapy | Italy | 46 |
| 1035 | bone marrow | aplastic anaemia | hematology | 2016 | standard therapy | Austria | 20 |
| 1036 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Croatia | 33 |
| 1037 | bone marrow | myeloproliferative syndrome | hematology | 2016 | standard therapy | Poland | 22 |
| 1038 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Ireland | 39 |
| 1039 | bone marrow | Diamond-Balckfan anaemia | hematology | 2016 | standard therapy | Germany | 2 |
| 1040 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Czech Republic | 9 |
| 1041 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Belarus | 15 |
| 1042 | bone marrow | juvenile myelomonocytic leukemia | hematology | 2016 | standard therapy | Germany | 3 |
| 1043 | bone marrow | acute myelogenous leukemia | hematology | 2016 | standard therapy | Finland | 45 |
| 1044 | bone marrow | anaemia | hematology | 2016 | standard therapy | Germany | 16 |
| 1045 | bone marrow | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Germany | 6 |
| 1046 | bone marrow | anaemia | hematology | 2016 | standard therapy | Italy | 5 |
| 1047 | bone marrow | high-risk acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 18 |
| 1048 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 26 |
| 1049 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Germany | 35 |
| 1050 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Canada | 59 |
| 1051 | peripheral blood | myelofibrosis | hematology | 2018 | standard therapy | Netherlands | 49 |
| 1052 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | United Kingdom | 29 |
| 1053 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | United Kingdom | 42 |
| 1054 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | USA | 74 |
| 1055 | peripheral blood | severe aplastic anaemia | hematology | 2018 | standard therapy | Germany | 18 |
| 1056 | peripheral blood | T-cell acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Germany | 7 |
| 1057 | peripheral blood | myeloma multiplex | hematology | 2018 | standard therapy | Lithuania | 56 |
| 1058 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | USA | 63 |
| 1059 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | United Kingdom | 46 |
| 1060 | peripheral blood | non-Hodgkin lymphoma | hematology | 2018 | standard therapy | Poland | 23 |
| 1061 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Poland | 66 |
| 1062 | peripheral blood | other myleofibrosis | hematology | 2018 | standard therapy | Poland | 57 |
| 1063 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Italy | 65 |
| 1064 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Poland | 48 |
| 1065 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | France | 46 |
| 1066 | peripheral blood | secondary acute myelogenous leukemia | hematology | 2018 | standard therapy | Poland | 58 |
| 1067 | peripheral blood | acute myeloid leukemia in first complete remission | hematology | 2018 | standard therapy | Germany | 61 |
| 1068 | peripheral blood | Hodgkin’s lymphoma | hematology | 2018 | standard therapy | Poland | 38 |
| 1069 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Spain | 34 |
| 1070 | peripheral blood | myelofibrosis | hematology | 2018 | standard therapy | Germany | 60 |
| 1071 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 72 |
| 1072 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | France | 50 |
| 1073 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | France | 33 |
| 1074 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | USA | 61 |
| 1075 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 45 |
| 1076 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 45 |
| 1077 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Italy | 67 |
| 1078 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Poland | 30 |
| 1079 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Poland | 71 |
| 1080 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | USA | 42 |
| 1081 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | Netherlands | 67 |
| 1082 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Germany | 56 |
| 1083 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 54 |
| 1084 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | USA | 72 |
| 1085 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | Poland | 59 |
| 1086 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Germany | 61 |
| 1087 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Poland | 51 |
| 1088 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Germany | 64 |
| 1089 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Germany | 61 |
| 1090 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | USA | 50 |
| 1091 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | USA | 47 |
| 1092 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Poland | 64 |
| 1093 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | Italy | 62 |
| 1094 | peripheral blood | B-cell Acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Germany | 41 |
| 1095 | peripheral blood | T-cell acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Poland | 13 |
| 1096 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | USA | 68 |
| 1097 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | USA | 62 |
| 1098 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | USA | 8 |
| 1099 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | USA | 54 |
| 1100 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | Poland | 67 |
| 1101 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | United Kingdom | 22 |
| 1102 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Slovenia | 54 |
| 1103 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Germany | 64 |
| 1104 | peripheral blood | myeloma multiplex | hematology | 2018 | standard therapy | USA | 57 |
| 1105 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Italy | 61 |
| 1106 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 46 |
| 1107 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 76 |
| 1108 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Poland | 50 |
| 1109 | peripheral blood | primary myelofibrosis, secondary acute myelogenous leukemia | hematology | 2018 | standard therapy | Germany | 53 |
| 1110 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | Poland | 64 |
| 1111 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Germany | 38 |
| 1112 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Germany | 8 |
| 1113 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 58 |
| 1114 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | Germany | 77 |
| 1115 | peripheral blood | non-Hodgkin lymphoma | hematology | 2018 | standard therapy | USA | 69 |
| 1116 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | Canada | 23 |
| 1117 | peripheral blood | B-cell Acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Switzerland | 50 |
| 1118 | peripheral blood | non-Hodgkin lymphoma | hematology | 2018 | standard therapy | USA | 70 |
| 1119 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 60 |
| 1120 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 71 |
| 1121 | peripheral blood | chronic myelomonocytic leukaemia | hematology | 2018 | standard therapy | USA | 39 |
| 1122 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | France | 25 |
| 1123 | peripheral blood | myelofibrosis | hematology | 2018 | standard therapy | Sweden | 56 |
| 1124 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Sweden | 60 |
| 1125 | peripheral blood | non-Hodgkin lymphoma | hematology | 2018 | standard therapy | Germany | 17 |
| 1126 | peripheral blood | non-Hodgkin lymphoma | hematology | 2018 | standard therapy | USA | 31 |
| 1127 | peripheral blood | chronic myelomonocytic leukaemia | hematology | 2018 | standard therapy | USA | 63 |
| 1128 | peripheral blood | Fanconi anaemia | hematology | 2018 | standard therapy | USA | 9 |
| 1129 | peripheral blood | acute lymphoblastic leukemia | hematology | 2018 | standard therapy | Poland | 49 |
| 1130 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Poland | 28 |
| 1131 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | Belgium | 68 |
| 1132 | peripheral blood | myelodysplastic syndrome | hematology | 2018 | standard therapy | USA | 66 |
| 1133 | peripheral blood | leukemia | hematology | 2018 | standard therapy | Germany | 34 |
| 1134 | peripheral blood | acute myelogenous leukemia | hematology | 2018 | standard therapy | UK | 37 |
| 1135 | peripheral blood | myelodysplastic syndrome, acute myelogenous leukemia | hematology | 2018 | standard therapy | USA | 74 |
| 1136 | peripheral blood | Hurler syndrome | hematology | 2017 | standard therapy | United Kingdom | 2 |
| 1137 | peripheral blood | myeloma multiplex | hematology | 2017 | standard therapy | Germany | 44 |
| 1138 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Poland | 60 |
| 1139 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 24 |
| 1140 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | United Kingdom | 51 |
| 1141 | peripheral blood | chronic myeloproliferative neoplasm blast crisis | hematology | 2017 | standard therapy | Germany | 29 |
| 1142 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 43 |
| 1143 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | France | 68 |
| 1144 | peripheral blood | chronic myeloid leukemia | hematology | 2017 | standard therapy | Turkey | 29 |
| 1145 | peripheral blood | severe aplastic anaemia | hematology | 2017 | standard therapy | Poland | 14 |
| 1146 | peripheral blood | Niemann–Pick disease | hematology | 2017 | standard therapy | Poland | 2 |
| 1147 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Iran | 17 |
| 1148 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Poland | 3 |
| 1149 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | USA | 63 |
| 1150 | peripheral blood | Common variable immunodeficiency, relapsed hemophagocytic syndrome | hematology | 2017 | standard therapy | Germany | 44 |
| 1151 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | France | 65 |
| 1152 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | Spain | 63 |
| 1153 | peripheral blood | diffuse large B-cell lymphoma | hematology | 2017 | standard therapy | Germany | 61 |
| 1154 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 56 |
| 1155 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 48 |
| 1156 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Austria | 54 |
| 1157 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | Denmark | 63 |
| 1158 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Hungary | 47 |
| 1159 | peripheral blood | no data | n/a | 2017 | standard therapy | France | 39 |
| 1160 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 54 |
| 1161 | peripheral blood | Langerhans Lymphohistiocytosis | hematology | 2017 | standard therapy | Czech Republic | 2 |
| 1162 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 75 |
| 1163 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Slovakia | 64 |
| 1164 | peripheral blood | chronic lymphocytic leukemia | hematology | 2017 | standard therapy | Belgium | 57 |
| 1165 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Russia | 32 |
| 1166 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 53 |
| 1167 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 47 |
| 1168 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | France | 43 |
| 1169 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 48 |
| 1170 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | France | 56 |
| 1171 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Italy | 47 |
| 1172 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 3 |
| 1173 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Spain | 20 |
| 1174 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Croatia | 64 |
| 1175 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | Germany | 66 |
| 1176 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 44 |
| 1177 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Poland | 46 |
| 1178 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 53 |
| 1179 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Netherlands | 66 |
| 1180 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Netherlands | 75 |
| 1181 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 61 |
| 1182 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Sweden | 63 |
| 1183 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 60 |
| 1184 | peripheral blood | myeloma multiplex | hematology | 2017 | standard therapy | Germany | 56 |
| 1185 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Lithuania | 59 |
| 1186 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 45 |
| 1187 | peripheral blood | hemophagocytosis | hematology | 2017 | standard therapy | USA | 52 |
| 1188 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Brazil | 12 |
| 1189 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Norway | 57 |
| 1190 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Belgium | 19 |
| 1191 | peripheral blood | chronic lymphocytic leukemia | hematology | 2017 | standard therapy | USA | 45 |
| 1192 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | USA | 65 |
| 1193 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 64 |
| 1194 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Belgium | 71 |
| 1195 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Turkey | 46 |
| 1196 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Belgium | 55 |
| 1197 | peripheral blood | no data | hematology | 2017 | standard therapy | Poland | 39 |
| 1198 | peripheral blood | aplastic anaemia | hematology | 2017 | standard therapy | United Kingdom | 23 |
| 1199 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | USA | 62 |
| 1200 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Germany | 50 |
| 1201 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Canada | 57 |
| 1202 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Italy | 58 |
| 1203 | peripheral blood | chronic myelomonocytic leukaemia | hematology | 2017 | standard therapy | Germany | 54 |
| 1204 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 32 |
| 1205 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | France | 75 |
| 1206 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | USA | 42 |
| 1207 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 63 |
| 1208 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Australia | 60 |
| 1209 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 53 |
| 1210 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Germany | 67 |
| 1211 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 33 |
| 1212 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 64 |
| 1213 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Germany | 56 |
| 1214 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 65 |
| 1215 | peripheral blood | B-cell Chronic lymphoblastic leukemia | hematology | 2017 | standard therapy | Germany | 48 |
| 1216 | peripheral blood | chronic lymphocytic leukemia | hematology | 2017 | standard therapy | Poland | 47 |
| 1217 | peripheral blood | osteopetrosis | hematology | 2017 | standard therapy | Israel | 3 |
| 1218 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | France | 56 |
| 1219 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 55 |
| 1220 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Canada | 56 |
| 1221 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Lithuania | 65 |
| 1222 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Switzerland | 75 |
| 1223 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 69 |
| 1224 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 51 |
| 1225 | peripheral blood | T-cell acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Australia | 30 |
| 1226 | peripheral blood | chronic lymphocytic leukemia | hematology | 2017 | standard therapy | Estonia | 67 |
| 1227 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 70 |
| 1228 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Belgium | 34 |
| 1229 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 68 |
| 1230 | peripheral blood | myeloproliferative neoplasms | hematology | 2017 | standard therapy | Poland | 7 |
| 1231 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 52 |
| 1232 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 59 |
| 1233 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | United Kingdom | 55 |
| 1234 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 62 |
| 1235 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Poland | 59 |
| 1236 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Canada | 67 |
| 1237 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 67 |
| 1238 | peripheral blood | β - Thalassemia Major | hematology | 2017 | standard therapy | India | 4 |
| 1239 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Czech Republic | 48 |
| 1240 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 53 |
| 1241 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 55 |
| 1242 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Czech Republic | 62 |
| 1243 | peripheral blood | acute myelogenous leukemia with myelodysplastic syndrome | hematology | 2017 | standard therapy | Germany | 64 |
| 1244 | peripheral blood | follicular CA | hematology | 2017 | standard therapy | South Africa | 42 |
| 1245 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Canada | 63 |
| 1246 | peripheral blood | chronic lymphocytic leukemia | hematology | 2017 | standard therapy | USA | 65 |
| 1247 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 35 |
| 1248 | peripheral blood | other myleofibrosis | hematology | 2017 | standard therapy | USA | 71 |
| 1249 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 64 |
| 1250 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 69 |
| 1251 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 39 |
| 1252 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 54 |
| 1253 | peripheral blood | prolymphocytic leukemia | hematology | 2017 | standard therapy | Belgium | 38 |
| 1254 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | France | 65 |
| 1255 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 23 |
| 1256 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Slovakia | 54 |
| 1257 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 35 |
| 1258 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Finland | 46 |
| 1259 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | Germany | 29 |
| 1260 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Germany | 63 |
| 1261 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Czech Republic | 12 |
| 1262 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 29 |
| 1263 | peripheral blood | no data | hematology | 2017 | standard therapy | Germany | 65 |
| 1264 | peripheral blood | chronic granulomatous disease | hematology | 2017 | standard therapy | Poland | 4 |
| 1265 | peripheral blood | no data | hematology | 2017 | standard therapy | Russia | 36 |
| 1266 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Turkey | 58 |
| 1267 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Turkey | 54 |
| 1268 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Netherlands | 51 |
| 1269 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 60 |
| 1270 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Germany | 49 |
| 1271 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 38 |
| 1272 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 38 |
| 1273 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Hungary | 32 |
| 1274 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Poland | 36 |
| 1275 | peripheral blood | T-cell acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 7 |
| 1276 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | USA | 62 |
| 1277 | peripheral blood | no data | hematology | 2017 | standard therapy | Kanada | 32 |
| 1278 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | France | 63 |
| 1279 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | France | 63 |
| 1280 | peripheral blood | primary Immunodeficiency | hematology | 2017 | standard therapy | Russia | 4 |
| 1281 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | France | 39 |
| 1282 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 62 |
| 1283 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 65 |
| 1284 | peripheral blood | chronic myelomonocytic leukaemia | hematology | 2017 | standard therapy | USA | 58 |
| 1285 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 67 |
| 1286 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 58 |
| 1287 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Netherlands | 51 |
| 1288 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 69 |
| 1289 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 19 |
| 1290 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Switzerland | 67 |
| 1291 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 43 |
| 1292 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | USA | 68 |
| 1293 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Amsterdam | 69 |
| 1294 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Israel | 11 |
| 1295 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Canada | 4 |
| 1296 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 42 |
| 1297 | peripheral blood | myeloproliferative neoplasms | hematology | 2017 | standard therapy | Poland | 7 |
| 1298 | peripheral blood | no data | hematology | 2017 | standard therapy | Poland | 58 |
| 1299 | peripheral blood | T-cell acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Australia | 25 |
| 1300 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Canada | 55 |
| 1301 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 68 |
| 1302 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 76 |
| 1303 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 52 |
| 1304 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Canada | 41 |
| 1305 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Russia | 49 |
| 1306 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | USA | 62 |
| 1307 | peripheral blood | primary Immunodeficiency | hematology | 2017 | standard therapy | Russia | 2 |
| 1308 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 60 |
| 1309 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 65 |
| 1310 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 51 |
| 1311 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 35 |
| 1312 | peripheral blood | no data | hematology | 2017 | standard therapy | Poland | 53 |
| 1313 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Belgium | 70 |
| 1314 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Germany | 64 |
| 1315 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Poland | 52 |
| 1316 | peripheral blood | chronic myeloid leukemia | hematology | 2017 | standard therapy | USA | 74 |
| 1317 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 30 |
| 1318 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 57 |
| 1319 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 31 |
| 1320 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 64 |
| 1321 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 60 |
| 1322 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 49 |
| 1323 | peripheral blood | severe aplastic anaemia | hematology | 2017 | standard therapy | Poland | 27 |
| 1324 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 53 |
| 1325 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 22 |
| 1326 | peripheral blood | severe aplastic anaemia | hematology | 2017 | standard therapy | Poland | 32 |
| 1327 | peripheral blood | B-cell Acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Germany | 44 |
| 1328 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Lithuania | 53 |
| 1329 | peripheral blood | other malignancy | hematology | 2017 | standard therapy | France | 59 |
| 1330 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Italy | 57 |
| 1331 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Russia | 54 |
| 1332 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 61 |
| 1333 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Hungary | 40 |
| 1334 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Netherlands | 53 |
| 1335 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Finland | 58 |
| 1336 | peripheral blood | chronic myelomonocytic leukaemia | hematology | 2017 | standard therapy | United Kingdom | 51 |
| 1337 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 68 |
| 1338 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 56 |
| 1339 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 62 |
| 1340 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Canada | 46 |
| 1341 | peripheral blood | primary myelofibrosis | hematology | 2017 | standard therapy | Germany | 29 |
| 1342 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 62 |
| 1343 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 59 |
| 1344 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 63 |
| 1345 | peripheral blood | chronic myelomonocytic leukaemia | hematology | 2017 | standard therapy | Italy | 61 |
| 1346 | peripheral blood | prolymphocytic leukemia | hematology | 2017 | standard therapy | Poland | 63 |
| 1347 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 53 |
| 1348 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Italy | 16 |
| 1349 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 17 |
| 1350 | peripheral blood | T-cell acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Greece | 28 |
| 1351 | peripheral blood | B-cell Acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Spain | 28 |
| 1352 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | France | 36 |
| 1353 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | Netherlands | 72 |
| 1354 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Belgium | 69 |
| 1355 | peripheral blood | chronic lymphocytic leukemia | hematology | 2017 | standard therapy | USA | 51 |
| 1356 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Norway | 56 |
| 1357 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Australia | 43 |
| 1358 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 63 |
| 1359 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 57 |
| 1360 | peripheral blood | chronic lymphocytic leukemia | hematology | 2017 | standard therapy | Germany | 7 |
| 1361 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 21 |
| 1362 | peripheral blood | B-cell Acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Germany | 64 |
| 1363 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Netherlands | 71 |
| 1364 | peripheral blood | primary myelofibrosis | hematology | 2017 | standard therapy | Poland | 32 |
| 1365 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 24 |
| 1366 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 62 |
| 1367 | peripheral blood | myelofibrosis | hematology | 2017 | standard therapy | USA | 47 |
| 1368 | peripheral blood | blastic plasmacytoid denditic cell neoplasm | hematology | 2017 | standard therapy | Germany | 56 |
| 1369 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 52 |
| 1370 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 66 |
| 1371 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 53 |
| 1372 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Sweden | 69 |
| 1373 | peripheral blood | no data | hematology | 2017 | standard therapy | Poland | 1 |
| 1374 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 66 |
| 1375 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 67 |
| 1376 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 55 |
| 1377 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | Netherlands | 65 |
| 1378 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 68 |
| 1379 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 63 |
| 1380 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Germany | 50 |
| 1381 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Sweden | 59 |
| 1382 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 63 |
| 1383 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Israel | 37 |
| 1384 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 23 |
| 1385 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Israel | 6 |
| 1386 | peripheral blood | severe aplastic anaemia | hematology | 2017 | standard therapy | Russia | 16 |
| 1387 | peripheral blood | secondary acute myelogenous leukemia | hematology | 2017 | standard therapy | Austria | 24 |
| 1388 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Turkey | 26 |
| 1389 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Germany | 46 |
| 1390 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 68 |
| 1391 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | USA | 55 |
| 1392 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 71 |
| 1393 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 53 |
| 1394 | peripheral blood | chronic myelomonocytic leukaemia | hematology | 2017 | standard therapy | Germany | 72 |
| 1395 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 58 |
| 1396 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | France | 61 |
| 1397 | peripheral blood | no data | hematology | 2017 | standard therapy | Canada | 55 |
| 1398 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 64 |
| 1399 | peripheral blood | myeloma multiplex | hematology | 2017 | standard therapy | USA | 57 |
| 1400 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 61 |
| 1401 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Canada | 22 |
| 1402 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 40 |
| 1403 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | USA | 69 |
| 1404 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 27 |
| 1405 | peripheral blood | myeloma multiplex | hematology | 2017 | standard therapy | Poland | 38 |
| 1406 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Germany | 57 |
| 1407 | peripheral blood | non-Hodgkin lymphoma | hematology | 2017 | standard therapy | USA | 69 |
| 1408 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 72 |
| 1409 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | Germany | 63 |
| 1410 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | United Kingdom | 24 |
| 1411 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 72 |
| 1412 | peripheral blood | Hodgkin’s lymphoma | hematology | 2017 | standard therapy | USA | 25 |
| 1413 | peripheral blood | chronic myeloid leukemia | hematology | 2017 | standard therapy | USA | 57 |
| 1414 | peripheral blood | myelodysplastic syndrome in Fanconi anaemia | hematology | 2017 | standard therapy | Italy | 23 |
| 1415 | peripheral blood | chronic myelomonocytic leukaemia | hematology | 2017 | standard therapy | Germany | 60 |
| 1416 | peripheral blood | myelodysplastic syndrome | hematology | 2017 | standard therapy | USA | 70 |
| 1417 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 10 |
| 1418 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Belgium | 26 |
| 1419 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | Poland | 37 |
| 1420 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | USA | 8 |
| 1421 | peripheral blood | no data | hematology | 2017 | standard therapy | Switzerland | 68 |
| 1422 | peripheral blood | acute myelogenous leukemia | hematology | 2017 | standard therapy | USA | 71 |
| 1423 | peripheral blood | acute lymphoblastic leukemia | hematology | 2017 | standard therapy | Poland | 13 |
| 1424 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | United Kingdom | 58 |
| 1425 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 56 |
| 1426 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Austria | 60 |
| 1427 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Australia | 62 |
| 1428 | peripheral blood | no data | n/a | 2016 | standard therapy | Czech Republic | 45 |
| 1429 | peripheral blood | chronic lymphocytic leukemia | hematology | 2016 | standard therapy | Slovakia | 52 |
| 1430 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 40 |
| 1431 | peripheral blood | no data | n/a | 2016 | standard therapy | Netherlands | 70 |
| 1432 | peripheral blood | no data | n/a | 2016 | standard therapy | Poland | 43 |
| 1433 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 18 |
| 1434 | peripheral blood | X-linked lymphoproliferative disease | hematology | 2016 | standard therapy | Russia | 12 |
| 1435 | peripheral blood | chronic lymphocytic leukemia | hematology | 2016 | standard therapy | Sweden | 61 |
| 1436 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 66 |
| 1437 | peripheral blood | no data | n/a | 2016 | standard therapy | Netherlands | 69 |
| 1438 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Columbia | 43 |
| 1439 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 64 |
| 1440 | peripheral blood | Hodgkin’s lymphoma | hematology | 2016 | standard therapy | Poland | 31 |
| 1441 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Czech Republic | 54 |
| 1442 | peripheral blood | T-cell leukemia/lymphoma | hematology | 2016 | standard therapy | Canada | 31 |
| 1443 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 54 |
| 1444 | peripheral blood | primary myelofibrosis | hematology | 2016 | standard therapy | Germany | 50 |
| 1445 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 18 |
| 1446 | peripheral blood | adrenoleukodystrophy | metabolic | 2016 | standard therapy | Poland | 1 |
| 1447 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 31 |
| 1448 | peripheral blood | no data | n/a | 2016 | standard therapy | Poland | 28 |
| 1449 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Sweden | 35 |
| 1450 | peripheral blood | no data | n/a | 2016 | standard therapy | Czech Republic | 1 |
| 1451 | peripheral blood | Wiskott-Aldrich syndrome | hematology | 2016 | standard therapy | Poland | 1 |
| 1452 | peripheral blood | no data | n/a | 2016 | standard therapy | Belgium | 30 |
| 1453 | peripheral blood | no data | n/a | 2016 | standard therapy | Germany | 71 |
| 1454 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 46 |
| 1455 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 29 |
| 1456 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Czech Republic | 56 |
| 1457 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 32 |
| 1458 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Czech Republic | 49 |
| 1459 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 50 |
| 1460 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 64 |
| 1461 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 42 |
| 1462 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 13 |
| 1463 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Slovakia | 8 |
| 1464 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Belgium | 46 |
| 1465 | peripheral blood | refractory anemia with excess blasts | hematology | 2016 | standard therapy | United Kingdom | 62 |
| 1466 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 40 |
| 1467 | peripheral blood | myelodysplastic syndrome - RAEB | hematology | 2016 | standard therapy | Poland | 56 |
| 1468 | peripheral blood | no data | n/a | 2016 | standard therapy | Sweden | 58 |
| 1469 | peripheral blood | Hodgkin’s lymphoma | hematology | 2016 | standard therapy | Germany | 32 |
| 1470 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 32 |
| 1471 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 66 |
| 1472 | peripheral blood | T Cell Lymphoma/ NOS - Not otherwise specified | hematology | 2016 | standard therapy | Germany | 55 |
| 1473 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 43 |
| 1474 | peripheral blood | no data | n/a | 2016 | standard therapy | Czech Republic | 59 |
| 1475 | peripheral blood | aplastic anaemia | hematology | 2016 | standard therapy | United Kingdom | 23 |
| 1476 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 73 |
| 1477 | peripheral blood | myelofibrosis | hematology | 2016 | standard therapy | Israel | 72 |
| 1478 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Australia | 61 |
| 1479 | peripheral blood | primary myelofibrosis | hematology | 2016 | standard therapy | Germany | 67 |
| 1480 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Ireland | 47 |
| 1481 | peripheral blood | no data | n/a | 2016 | standard therapy | Germany | 17 |
| 1482 | peripheral blood | no data | n/a | 2016 | standard therapy | France | 59 |
| 1483 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 66 |
| 1484 | peripheral blood | chronic lymphocytic leukemia | hematology | 2016 | standard therapy | Germany | 62 |
| 1485 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 47 |
| 1486 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | France | 67 |
| 1487 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Lithuania | 15 |
| 1488 | peripheral blood | Hodgkin’s lymphoma | hematology | 2016 | standard therapy | United Kingdom | 18 |
| 1489 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Czech Republic | 37 |
| 1490 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | France | 24 |
| 1491 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Canada | 13 |
| 1492 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Hungary | 57 |
| 1493 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Belgium | 56 |
| 1494 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 38 |
| 1495 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 52 |
| 1496 | peripheral blood | chronic myelomonocytic leukemia, minimal residual disease | hematology | 2016 | standard therapy | Poland | 50 |
| 1497 | peripheral blood | myeloma multiplex | hematology | 2016 | standard therapy | Germany | 63 |
| 1498 | peripheral blood | Fanconi anaemia | hematology | 2016 | standard therapy | Estonia | 7 |
| 1499 | peripheral blood | plasma cell disorder | hematology | 2016 | standard therapy | France | 47 |
| 1500 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 35 |
| 1501 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 72 |
| 1502 | peripheral blood | myeloma multiplex | hematology | 2016 | standard therapy | Poland | 51 |
| 1503 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Spain | 58 |
| 1504 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Estonia | 62 |
| 1505 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Hungary | 46 |
| 1506 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Hungary | 20 |
| 1507 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 51 |
| 1508 | peripheral blood | primary Immunodeficiency | hematology | 2016 | standard therapy | Russia | 5 |
| 1509 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | United Kingdom | 62 |
| 1510 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 69 |
| 1511 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Australia | 51 |
| 1512 | peripheral blood | no data | n/a | 2016 | standard therapy | Netherlands | 58 |
| 1513 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Spain | 38 |
| 1514 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Lithuania | 23 |
| 1515 | peripheral blood | chronic myeloid leukemia | hematology | 2016 | standard therapy | Germany | 62 |
| 1516 | peripheral blood | Hodgkin’s lymphoma | hematology | 2016 | standard therapy | Germany | 32 |
| 1517 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Germany | 27 |
| 1518 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 30 |
| 1519 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Turkey | 55 |
| 1520 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Israel | 63 |
| 1521 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Turkey | 37 |
| 1522 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 66 |
| 1523 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Turkey | 38 |
| 1524 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 65 |
| 1525 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 46 |
| 1526 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 18 |
| 1527 | peripheral blood | Hodgkin’s lymphoma | hematology | 2016 | standard therapy | Netherlands | 38 |
| 1528 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Turkey | 48 |
| 1529 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 61 |
| 1530 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 67 |
| 1531 | peripheral blood | no data | n/a | 2016 | standard therapy | Poland | 55 |
| 1532 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 32 |
| 1533 | peripheral blood | T-cell acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Germany | 19 |
| 1534 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | United Kingdom | 68 |
| 1535 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 59 |
| 1536 | peripheral blood | myelodysplastic syndrome- RCMD | hematology | 2016 | standard therapy | Czech Republic | 32 |
| 1537 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Belgium | 65 |
| 1538 | peripheral blood | myelofibrosis | hematology | 2016 | standard therapy | Netherlands | 66 |
| 1539 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Switzerland | 2/3 |
| 1540 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Israel | 36 |
| 1541 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 66 |
| 1542 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Denmark | 68 |
| 1543 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Spain | 15 |
| 1544 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Italy | 52 |
| 1545 | peripheral blood | chronic myelomonocytic leukaemia | hematology | 2016 | standard therapy | Finland | 53 |
| 1546 | peripheral blood | no data | n/a | 2016 | standard therapy | Turkey | 4 |
| 1547 | peripheral blood | leukemia | hematology | 2016 | standard therapy | Lithuania | 53 |
| 1548 | peripheral blood | T-cell acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Serbia | 21 |
| 1549 | peripheral blood | myeloproliferative syndrome | hematology | 2016 | standard therapy | Poland | 52 |
| 1550 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | France | 63 |
| 1551 | peripheral blood | no data | n/a | 2016 | standard therapy | Poland | 44 |
| 1552 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Czech Republic | 60 |
| 1553 | peripheral blood | T-cell acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Austria | 41 |
| 1554 | peripheral blood | primary myelofibrosis | hematology | 2016 | standard therapy | Switzerland | 67 |
| 1555 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | United Kingdom | 20 |
| 1556 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Brazil | 37 |
| 1557 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | France | 60 |
| 1558 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 61 |
| 1559 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Turkey | 51 |
| 1560 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | France | 28 |
| 1561 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 65 |
| 1562 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 53 |
| 1563 | peripheral blood | Lymphoblastic Lymphoma | hematology | 2016 | standard therapy | Italy | 33 |
| 1564 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Slovakia | 30 |
| 1565 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Belgium | 9 |
| 1566 | peripheral blood | myeloma multiplex | hematology | 2016 | standard therapy | Poland | 38 |
| 1567 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 39 |
| 1568 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Austria | 61 |
| 1569 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | New Zealand | 59 |
| 1570 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Australia | 62 |
| 1571 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 65 |
| 1572 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Portugal | 41 |
| 1573 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | France | 59 |
| 1574 | peripheral blood | SAA / Amyloidosis | hematology | 2016 | standard therapy | United Kingdom | 45 |
| 1575 | peripheral blood | chronic myeloid leukemia | hematology | 2016 | standard therapy | Finland | 46 |
| 1576 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 50 |
| 1577 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Italy | 66 |
| 1578 | peripheral blood | non-Hodgkin lymphoma | hematology | 2016 | standard therapy | Russia | 38 |
| 1579 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 20 |
| 1580 | peripheral blood | myelofibrosis | hematology | 2016 | standard therapy | France | 67 |
| 1581 | peripheral blood | B-cell Acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Belgium | 44 |
| 1582 | peripheral blood | non-Hodgkin lymphoma | hematology | 2016 | standard therapy | Poland | 58 |
| 1583 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Germany | 72 |
| 1584 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | United Kingdom | 68 |
| 1585 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 63 |
| 1586 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | France | 56 |
| 1587 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 54 |
| 1588 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 24 |
| 1589 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Greece | 9 |
| 1590 | peripheral blood | chronic myeloid leukemia | hematology | 2016 | standard therapy | Germany | 40 |
| 1591 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 15 |
| 1592 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 37 |
| 1593 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Russia | 44 |
| 1594 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 59 |
| 1595 | peripheral blood | non-Hodgkin lymphoma | hematology | 2016 | standard therapy | Russia | 32 |
| 1596 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 62 |
| 1597 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 55 |
| 1598 | peripheral blood | composite lymphoma | hematology | 2016 | standard therapy | Germany | 51 |
| 1599 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 30 |
| 1600 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Germany | 33 |
| 1601 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Italy | 58 |
| 1602 | peripheral blood | high-risk acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Poland | 5 |
| 1603 | peripheral blood | acute myelogenous leukemia M2/M4 | hematology | 2016 | standard therapy | Germany | 59 |
| 1604 | peripheral blood | non-Hodgkin lymphoma | hematology | 2016 | standard therapy | Netherlands | 39 |
| 1605 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | Italy | 21 |
| 1606 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Spain | 50 |
| 1607 | peripheral blood | plasma cell disorder | hematology | 2016 | standard therapy | France | 54 |
| 1608 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | United Kingdom | 47 |
| 1609 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Canada | 47 |
| 1610 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 67 |
| 1611 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 62 |
| 1612 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Italy | 63 |
| 1613 | peripheral blood | acute myelogenous leukemia | hematology | 2016 | standard therapy | Poland | 19 |
| 1614 | peripheral blood | T-cell-prolymphocytic leukemia | hematology | 2016 | standard therapy | United Kingdom | 61 |
| 1615 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | USA | 69 |
| 1616 | peripheral blood | acute lymphoblastic leukemia | hematology | 2016 | standard therapy | France | 35 |
| 1617 | peripheral blood | severe aplastic anaemia | hematology | 2016 | standard therapy | Russia | 18 |
| 1618 | peripheral blood | myelodysplastic syndrome | hematology | 2016 | standard therapy | Germany | 66 |
| {{$index+1}} | {{item.source}} | {{item.indication}} | {{item.area}} | {{item.year}} | {{item.therapy}} | {{item.country}} | {{item.age | number}} |